Filanesib is a potent Kinesin Spindle Protein (KSP) inhibitor that caused marked tumor regression in preclinical models of human solid tumors and human leukemias, often leading to durable responses.
Investigated for use/treatment in cancer/tumors (unspecified).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.